These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 2971866)

  • 1. [Cilazapril in essential hypertension. A study of one year of continuous treatment].
    Lange H; Belz GG; Tschollar W; Wolf GK
    Med Klin (Munich); 1988 Sep; 83(17):554-8. PubMed ID: 2971866
    [No Abstract]   [Full Text] [Related]  

  • 2. [Cilazapril in essential hypertension. A placebo-controlled double-blind study to establish the dosage].
    Belz GG; Lange H; Tschollar W; Neis W
    Med Klin (Munich); 1986 Jul; 81(15-16):524-9. PubMed ID: 2946925
    [No Abstract]   [Full Text] [Related]  

  • 3. [New, in Austria registered specialty drugs. Inhibace (cilazapril)].
    Töglhofer W
    Wien Klin Wochenschr; 1992; 104(6):178-82. PubMed ID: 1533738
    [No Abstract]   [Full Text] [Related]  

  • 4. Antihypertensive duration of action of cilazapril in patients with mild to moderate essential hypertension.
    Kobrin I; Güntzel P; Viskoper R; Paran E; Zimlichman R
    Drugs; 1991; 41 Suppl 1():31-6. PubMed ID: 1712270
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cilazapril: a new non-thiol-containing angiotensin-converting enzyme inhibitor. Worldwide clinical experience in hypertension.
    Kögler P
    Am J Med; 1989 Dec; 87(6B):50S-55S. PubMed ID: 2532461
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Beta-blockers and ACE-inhibitors--further evidence for therapeutic benefit of this combination in hypertension.
    Erb KA; Breithaupt K; Belz GG
    J Hum Hypertens; 1990 Feb; 4(1):63. PubMed ID: 1971655
    [No Abstract]   [Full Text] [Related]  

  • 7. Resistance to the actions of atrial natriuretic factor in insulin-dependent diabetic hypertensives and improvement with angiotensin converting enzyme inhibitor treatment.
    Fioretto P; Muollo B; Ben GP; Mollo F; Frigato F; Opocher G; Trevisan R; Carraro A; Sambataro M; Nosadini R
    J Hypertens Suppl; 1991 Dec; 9(6):S262-3. PubMed ID: 1840196
    [No Abstract]   [Full Text] [Related]  

  • 8. Cilazapril: an overview of its efficacy and safety in hypertension.
    Szucs T; Schneeweiss A
    Cardiology; 1992; 80(1):34-41. PubMed ID: 1532534
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glucose tolerance and insulin secretion in essential hypertension after treatment with an angiotensin converting enzyme inhibitor.
    Santoro D; Natali A; Galvan AQ; Masoni A; Gazzetti P; Ferrannini E
    J Hypertens Suppl; 1991 Dec; 9(6):S406-7. PubMed ID: 1840204
    [No Abstract]   [Full Text] [Related]  

  • 10. The influence of prostaglandin inhibition by indomethacin on blood pressure and renal function in hypertensive patients treated with cilazapril.
    Kirch W; Stroemer K; Hoogkamer JF; Kleinbloesem CH
    Br J Clin Pharmacol; 1989; 27 Suppl 2(Suppl 2):297S-301S. PubMed ID: 2527542
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evolving role of angiotensin-converting enzyme inhibitors in cardiovascular therapy. Second International Symposium on Cilazapril. February 9 to 11, 1989, Basel, Switzerland. Proceedings.
    Am J Med; 1989 Dec; 87(6B):1S-99S. PubMed ID: 2532456
    [No Abstract]   [Full Text] [Related]  

  • 12. Anti-ischemic effects of cilazapril in patients with both hypertension and angina pectoris. Preliminary report of a pilot study.
    Schneeweiss A; Marmor AT; Rettig-Stürmer G
    Cardiology; 1991; 79(1):46-8. PubMed ID: 1838032
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative effects of 2.5 and 5 mg cilazapril versus placebo on daily blood pressure load.
    Poirier L; Pyzyk M; Provencher P; Lacourcière Y
    Am J Hypertens; 1991 Nov; 4(11):913-5. PubMed ID: 1838693
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A single dose of cilazapril improves diastolic function in hypertensive patients.
    Marmor A; Green T; Krakuer J; Szucs T; Schneeweiss A
    Am J Med; 1989 Dec; 87(6B):61S-63S. PubMed ID: 2532463
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Angiotensin-converting enzyme inhibitor in a human model of restenosis. MERCATOR ("Multicenter European Research Trial with Cilazapril after Angioplasty to Prevent Transluminal Coronary Obstruction and Restenosis") Study Group.
    Heyndrickx GR
    Basic Res Cardiol; 1993; 88 Suppl 1():169-82. PubMed ID: 8357332
    [No Abstract]   [Full Text] [Related]  

  • 16. Converting-enzyme inhibitors in the treatment of hypertension.
    Williams GH
    N Engl J Med; 1988 Dec; 319(23):1517-25. PubMed ID: 3054561
    [No Abstract]   [Full Text] [Related]  

  • 17. Effect of a new angiotensin converting enzyme inhibitor, cilazapril, on circulating atrial natriuretic factor during exercise in patients with essential hypertension.
    Kohno M; Yasunari K; Murakawa K; Yokokawa K; Horio T; Kurihara N; Takeda T
    J Hypertens Suppl; 1989 Dec; 7(6):S298-9. PubMed ID: 2534417
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of cilazapril on hypertension, sleep, and apnea.
    Peter JH; Gassel W; Mayer J; Herrer-Mayer B; Penzel T; Schneider H; Weichler U; Weber K; von Wichert P
    Am J Med; 1989 Dec; 87(6B):72S-78S. PubMed ID: 2532465
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Experience with endralazine in the treatment of essential hypertension].
    Dvorák I; Dvorák M; Blaha M; Kubesová H; Havlát F; Nĕmcová H
    Vnitr Lek; 1984 Jan; 30(1):42-7. PubMed ID: 6364562
    [No Abstract]   [Full Text] [Related]  

  • 20. Delaying disease.
    Br J Hosp Med; 1991 Nov; 46(5):345. PubMed ID: 1835663
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.